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ABSTRACT
OBJECTIVES. Plasminogen activator inhibitor-1 counterregulates cell migration, adhe-
sion, and tissue repair. The PAI1 4G/5G promoter polymorphism has an effect on
expression levels of PAI1. After a first acute otitis media episode, children are at
increased risk for a next episode. Because the PAI1 4G allele is associated with
higher plasminogen activator inhibitor-1 production and, hence, decreased tissue
repair, we hypothesize that this allele may contribute to increased recurrence of
acute otitis media.
PATIENTS AND METHODS. The PAI1 4G/5G polymorphism was genotyped in 348 Dutch
children aged 1 to 7 years who were suffering from recurrent acute otitis media
and participating in a randomized, controlled trial and 463 healthy control sub-
jects, representative of the general population.
RESULTS.No significant difference in PAI1 genotype distribution between the whole
acute otitis media group and control subjects was observed. However, children
with the PAI1 4G/4G genotype had an increased risk of more frequent acute otitis
media episodes compared with those who were homozygous for the 5G variant,
also after correction for cofactors. This finding was attributable to children 4
years of age.
CONCLUSIONS.Our findings suggest that the PAI1 4G/4G genotype is associated with
an increased risk for the otitis-prone condition, potentially because of impaired
healing after a previous otitis media episode.
www.pediatrics.org/cgi/doi/10.1542/
peds.2006-1390
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ACUTE OTITIS MEDIA (AOM) is the most commoninfection in children, but the number of AOM ep-
isodes varies markedly between patients. Approximately
10% to 15% of all children suffer from 4 episodes per
year and are considered otitis prone.1–3 One of the most
prominent risk factors seems to be a first episode of AOM
early in life predisposing to a next event.4,5 Other issues
affecting the risk of developing recurrent middle ear
infections include host factors like gender, age, atopy,
and ethnic background.6 Environmental factors associ-
ated with recurrent AOM episodes are microbial expo-
sure, like in day care or from older siblings, or triggers,
like lack of breastfeeding or exposure to tobacco smoke.
Often there is a family history of otitis media.4,6,7 Twin
studies have shown a heritability of 57% for acute ear
infections and 72% for chronic ear infections.8–12 Fur-
thermore, the correlation for recurrent otitis media is
twofold higher in monozygotic twins (65%–71%) com-
pared with dizygotic twins (25%–34%).13 Genetic factors
involved in inflammation and tissue repair may play a
role in the development of recurrent AOM episodes and
the otitis-prone condition. Delayed downregulation of
the inflammatory response to infections in the middle
ear cavity may play a role in priming the individual for
additional AOM episodes. Plasminogen activator inhibi-
tor-1 (PAI-1) is known to have an important role in
fibrinolysis.14,15 In addition, PAI-1 is involved in the in-
flammatory reaction, inhibits cell adhesion and migra-
tion, and delays tissue repair.16,17 The 4G/5G insertion-
deletion polymorphism at position 675 of the PAI1
gene is known to influence the expression of PAI-1.18,19
Individuals homozygous for the 4G allele have higher
PAI-1 concentrations in peripheral blood than those
with the 4G/5G or 5G/5G genotypes.20,21 The PAI1 4G
allele has been reported previously to be associated with
asthma, as well as with increased morbidity and mortal-
ity in meningococcal disease.20,22–25
We hypothesized that the PAI1 4G/4G genotype,
known to result in high PAI-1 concentrations, which is
associated with decreased tissue integrity, is associated
with recurrence of otitis media. In this study, we inves-
tigated the association between this PAI1 polymorphism
and recurrent AOM. Our results show that 4G homozy-
gous individuals have an increased risk for an otitis-
prone condition, especially under the age of 4 years.
METHODS
Participants
Patients who initially participated in a randomized, con-
trolled study on prevention of recurrent AOM by pneu-
mococcal vaccinations were included in this study.26 Par-
ents were informed about the study by primary care
physicians, pediatricians, and otolaryngologists from
across the Netherlands. Children were enrolled in the
study after obtaining approval of the medical ethical
committee of the Utrecht University Medical Centre and
informed consent from the parents or guardians. DNA
was available from 348 Dutch white children, 1 to 7
years of age, who were suffering from recurrent AOM
defined as 2 AOM episodes in the preceding year. The
number of AOM episodes before vaccination was based
both on parental report (AOM defined as having 1 of
the symptoms: acute earache, new-onset otorrhea, irri-
tability, and fever) and on clinical information of the
diagnosis by a physician. In the present study cohort,
122 children suffered from 2 to 3 otitis media episodes in
the year preceding inclusion, whereas 226 suffered from
4 episodes (otitis-prone condition).3 No children with
2 AOM episodes were included in the vaccination trial.
In addition, children with primary or secondary immu-
nodeficiency, cystic fibrosis, immotile cilia syndrome,
chromosomal abnormalities such as Down syndrome,
and craniofacial abnormalities such as cleft palate were
excluded from the study. The history of atopy, defined as
eczema, hay fever, recurrent wheezing, or asthma, and
the number of AOM episodes in the year before inclu-
sion were assessed by the questionnaire filled out by all
of the patients and their parents at inclusion in the
study. Otorrhea duration was assessed in 214 children
for whom PAI1 genotypes were available. Patient char-
acteristics are described in Table 1. Healthy adult Dutch
white control subjects (n  463) were derived from the
Dutch Blood Bank Sanquin. No records of previous his-
tory regarding AOM were available for these control
subjects; however, in the general population, a total
number of 3.2 AOM episodes is expected in child-
hood.3 This implies that control subjects will have had,
on average, much fewer AOM episodes per year than the
patients. Blood was sampled for DNA isolation. DNA
isolation from donor buffy coats was performed accord-
ing to standard protocols using a QIAamp DNA mini kit
(Qiagen, Valencia, CA).
Experimental Procedures
PAI1 675 genotype (rs1799889) was determined using
single base extension analysis, a technique commonly
used in our laboratory (ABI Prism, SNaPshot Multiplex
kit; Applied Biosystems, Foster City, CA). The genomic
region of interest was amplified using polymerase chain
reaction (37 cycles; annealing temperature of 60°C; total
volume of 10 L) with the following primers: forward,
5-CAGCCAGACAAGGTTGTT-3, and reverse 5-CCAC-
CCGGTGCTCT-3. Amplification resulted in a 265-nu-
cleotide polymerase chain reaction product. After puri-
fication with Shrimp Alkaline Phosphatase and
Exonuclease I (both from Amersham Biosciences, Upp-
sala, Sweden), a single base extension with fluorescently
labeled dideoxynucleotide triphosphates was performed
using the reverse primer 5-TTTTTGATACACGGCT-
GACTCCCC-3. The poly-T tail allows us to distinguish
primers in a multiplex analysis for which this assay was
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originally designed. The products generated were ana-
lyzed on an ABI Prism 3100 genetic analyzer using Ge-
neScan Analysis Software (Applied Biosystems). When
no clear genotype was obtained or no consensus was
reached between 2 independent investigators, genotypes
were excluded from the analyses.
Statistical Analyses
Statistical analyses were performed by using SPSS 11.0
(SPSS Inc, Chicago, IL). A comparison of genotype fre-
quencies was made between patients and blood donor
control subjects assuming a multiplicative model.27 Bi-
nomial variables were analyzed using Pearson’s 2 test or
Fisher’s exact test when appropriate. Continuous vari-
ables were compared for the different genotypes using
the Mann-Whitney U test (nonparametric) or t test (nor-
mal distribution). Within the patient sample, only geno-
type distributions of children suffering from 2 to 3 epi-
sodes per year before vaccination were compared with
those of individuals who had 4 episodes after correc-
tion for age at study entry, gender, number of siblings,
and the log-transformed age at the time of the first
episode of AOM, using binary logistic regression. The
log-transformed age at the time of the first AOM episode
was included in the analysis, because age at the first
AOM episode itself did not show a normal distribution
and an early first infection predisposes to a second AOM
episode. A child who has had a first AOM episode at a
younger age has had a longer period of time to develop
multiple AOM episodes than a child of the same age who
suffered from the first infection at a later age. Because
the interaction between the age at the first AOM episode
and the age of inclusion was significant, this was ac-
counted for in the analyses. Because the pathogenesis of
AOM in young children may differ from older children
because of an immature immune system and different
anatomic features such as the Eustachian tube, we also
analyzed separately the frequencies of the number of
AOM episodes in the year before inclusion in patients 1
to 4 years of age and patients4 years. Presence of atopy
did not differ between the otitis-prone children and
those with fewer episodes. Because asthma cannot, by
definition, be diagnosed in children 6 years of age,
which applies to the main fraction of our patient cohort,
recurrent wheezing and asthma as reported by the par-
ents were considered the same in the statistical analyses.
In addition to the multiplicative model, the effect of PAI1
genotype on the number of AOM episodes was also
assessed comparing 4G/4G homozygotes with those ho-
mozygous for the 5G allele.
RESULTS
The PAI1 4G/4G Genotype Is Not AssociatedWith Initial
Susceptibility to AOM
The PAI1 675 polymorphism was successfully geno-
typed in 463 control subjects and 317 children with
recurrent AOM. PAI1 genotype frequencies in the con-
trol population were in Hardy-Weinberg equilibrium,
and the allele frequencies were similar to results pub-
lished previously.24 The distribution of genotypes in con-
trol subjects was as follows: 5G/5G, 99 (21.4%); 4G/5G,
241 (52.1%); and 4G/4G, 123 (26.6%). A significant
difference in genotype distribution was only found be-
tween control subjects and those patients suffering from
4 episodes of AOM (P  .02). No difference was ob-
served between patients having 2 to 3 AOM episodes a
year and control subjects (P  .34; Table 2).
Related Epidemiologic Findings
In our patient population, log-transformed age at first
AOM, gender, and the number of siblings were related to
AOM recurrence rates (Table 1). Children who suffered
from 4 episodes in the year before inclusion had their
TABLE 1 Characteristics of Patients With Recurrent AOM
Characteristics 2–3 AOM Episodes
(N 122)
4 AOM Episodes
(N 226)
Pa
Male gender, n (%) 84 (69) 128 (57) .03
Age, median (range), y 2.42 (1.0–6.3) 2.10 (1.0–7.0) .40
Age group (12–48 mo), n (%) 84 (69) 180 (80) .03
Age at ﬁrst AOM, geometric mean (SD), mo 10.1 (2.0) 7.7 (2.1) .001
Breastfeeding3 mo, n (%) 57 (47) 96 (43) .50
Tobacco smoke exposure indoors, n (%) 41 (34) 70 (31) .63
Day care
At age 12–24 mo, n/N (%) 22/44 (50) 42/99 (42) .47
At age 25–48 mo, n/N (%) 70/78 (90) 113/127 (89) 1.00
No. of siblings, median (range); mean 1.0 (0–3); 0.93 1.0 (0–7); 1.17 .02
Family history positive for AOM
Parents (121/225), n (%) 79 (65) 131 (58) .21
Siblings, n/N (%) 48/86 (56) 98/182 (54) .79
Atopy, n (%)b 54 (44) 117 (52) .22
a Fisher’s exact test, Mann-Whitney U test, and t test were performed when appropriate.
b Atopy was deﬁned as having eczema, hay fever, or recurrent wheezing or asthma.
PEDIATRICS Volume 120, Number 2, August 2007 e319
first AOM episode at a significantly younger age com-
pared with the children suffering from 2 to 3 episodes.
Although the majority in the total group of children with
AOMwere boys, girls were overrepresented in the group
of children suffering from 4 AOM episodes when com-
pared with the group of children with 2 to 3 AOM
episodes. The number of siblings was higher in the otitis-
prone group compared with the children with 2 to 3
episodes. Age at inclusion was not significantly different
when comparing the group of children suffering from 2
to 3 AOM episodes with the group with 4 episodes.
However, when children were divided into groups under
and over the age of 4 years, the distribution of AOM
frequency differed significantly (Fig 1). The occurrence
of atopy and the presence of a family history positive for
AOM did not differ between children with 2 to 3 vs 4
episodes of AOM.
The PAI1 4G/4G Genotype Is AssociatedWith the Otitis-Prone
Condition in Children<4 Years of Age
Comparing patients having 2 to 3 AOM episodes to those
with 4, the log-odds ratio (OR) of the 4G/4G versus
5G/5G genotype was 2 times the logOR of the 4G/5G
versus 5G/5G genotype (OR: 2.52; logOR: 0.4 and OR:
1.52; logOR: 0.19, respectively; Table 2). Hence, the 4G
allele probably has a multiplicative effect on AOM re-
currence rate.27 After correction for confounding factors
as described in “Statistical Analyses,” we still found that
the PAI1 4G/4G genotype was associated with recur-
rence of disease in patients (P .01, crude OR: 1.59; P
.03, adjusted OR: 1.52). The PAI1 4G/4G individuals had
an increased risk for 4 AOM episodes compared with
patients homozygous for the 5G variant (P  .01, crude
OR: 2.52; P  .03, adjusted OR: 2.31). Because the
distribution of the number of AOM episodes differed
between the groups of children 1 to 4 years of age and
4 years of age, these groups were also analyzed sepa-
rately (Fig 1). The association of the PAI1 4G/4G geno-
TABLE 2 Comparison of PAI1 4G/5G Genotype Distribution in Patients With Recurrent Otitis Media and Control Subjects
PAI1 4G/5G Control Subjects
(N 463),
n (%)
2–3 Episodes of AOM
(N 115), n (%)
4 Episodes of AOM
(N 202), n (%)
4G/4G vs 5G/5G 2–3 vs4,
Crude OR (P)d
2–3 vs4,
Adjusted OR (P)c,d
Control vs
2–3, OR (P)a
Control vs
4, OR (P)b
All patients 1.59 (.01) 1.52 (.03)
5G/5G 99 (21.4) 26 (22.6) 28 (13.9) 1.00e 1.00e 1.00e 1.00e
4G/5G 241 (52.1) 65 (55.6) 109 (54.0) 1.03 (.92) 1.60 (.05) 1.56 (.16) 1.57 (.18)
4G/4G 123 (26.6) 24 (20.9) 65 (32.2) 0.74 (.34) 1.87 (.02) 2.52 (.01)f 2.31 (.03)f
Patients4 y 1.75 (.01)d 1.72 (.02)d
5G/5G 18 (23.4) 25 (15.8) 1.00e 1.00e
4G/5G 48 (62.3) 85 (53.8) 1.28 (.50) 1.32 (.47)
4G/4G 11 (14.3) 48 (30.4) 3.14 (.01)f 2.97 (.02)f
Patients4 y 1.53 (.21)d 1.17 (.69)d
5G/5G 8 (21.1) 3 (6.8) 1.00e 1.00e
4G/5G 17 (44.7) 24 (54.5) 3.77 (.08) 5.25 (.06)
4G/4G 13 (34.2) 17 (38.6) 3.49 (.11)f 2.50 (.30)f
a Data are for patients with 2 to 3 episodes of AOM versus control subjects: P .45 (2).
b Data are for patients with4 episodes of AOM versus control subjects: P .05 (2).
c Adjusted ORs depicted were corrected for age at study entry, gender, number of siblings, and the log-transformed age at the time of the ﬁrst episode of AOM.
d ORs represent the effect of the PAI1 4G/5G polymorphism (binary logistic regression analysis, multiplicative model).
e The reference OR is 1.00.
f Data are for 4G homozygous versus 5G homozygous patients, crude or adjusted, binary logistic regression analysis. In this analysis, the PAI1675 polymorphism was included in the model as a
categorical variable.
FIGURE 1
Distribution of the number of AOM episodes for different age categories at the time of
inclusion. The number of patients (age category in years) for the group of childrenwith 2
to 3 AOMepisodes in the year before inclusion is 44 (1–2), 27 (2–3), 13 (3–4), 16 (4–5), 17
(5–6), and 5 (6–7). The number of patients (age category) for the group of children with
4 AOMepisodes in the year before inclusion is 99 (1–2), 44 (2–3), 37 (3–4), 12 (4–5), 20
(5–6), and 14 (6–7). The distribution of 2 to 3 vs 4 AOM episodes differs between
patients4 and4 years of age (P .03).
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type with the otitis-prone condition was only found in
the group of children 1 to 4 years of age (P  .01, crude
OR: 1.75; P  .02, adjusted OR: 1.72; Table 2). Compar-
ing the children with PAI1 4G/4G genotype with those
homozygous for the 5G allele yielded a crude OR of 3.14
(P  .01; adjusted OR: 2.97, P  .02). The PAI1 4G/4G
genotype was not significantly associated with the otitis-
prone condition in children4 years of age. The number
of days with otorrhea showed a trend toward longer
duration in the 4G homozygous children (geometric
mean days [SD] for genotypes: 5G/5G, 5.3 [3.9]; 4G/5G,
6.5 [4.0]; and 4G/4G, 7.2 [4.2]). This was, however, not
significant (P  .66, analysis of variance).
DISCUSSION
In this study we show that, in the patient group with a
history of2 AOM episodes, children 1 to 4 years of age,
with the PAI1 4G/4G genotype, which is related to high
PAI-1 levels, have increased risk for more frequent re-
current AOM.18,19 The association is significant even after
correction for possible confounding factors, with only a
minimal change in ORs. PAI-1 inhibits cellular migration
and invasion, processes essential in tissue repair in in-
flammatory disease.16,17 Hence, higher PAI-1 levels might
result in longer persistence of tissue inflammation or
abnormally repaired tissue prone to bacterial coloniza-
tion and new infections.
Two possible mechanisms for PAI-1 interaction and
inhibition of tissue repair have been proposed. First,
PAI-1 may inhibit a proteolytic cascade at the cell surface
that results in matrix destruction, allowing cellular mi-
gration and invasion for tissue repair. The proteolytic
cascade mechanism involves the activation of surface-
bound plasminogen by surface-bound urokinase plas-
minogen activator (uPA). PAI-1 can bind to uPA on the
cell surface and inhibit its proteolytic activity and, hence,
tissue repair.15,28,29 A second proposed pathway involves
competitive binding of PAI-1 and integrin to vitronectin.
Both share the same binding site region on vitronectin.
Vitronectin/integrin interaction is needed for cell migra-
tion and adhesion. The inhibiting effect of PAI-1 is ne-
gated when excess nonsurface-bound uPA forms a com-
plex with PAI-1 resulting in a release of PAI-1 from
vitronectin, which is then available for interaction with
integrin, favoring cell adhesion.30
A possible role for high PAI-1 concentrations in the
stronger inhibition of healing of inflamed otolaryngeal
tissue that may, thus, favor an otitis-prone condition is
supported by the results of Hansson et al31 that imply a
further role for PAI-1 and plasminogen in tissue repair.
They have shown that perforated tympanic membranes
(TMs) of plasminogen-deficient mice exhibit reduced
healing 15 days after myringectomy compared with TM
fromwild-type mice. Intravenous administration of plas-
minogen, in plasminogen-deficient mice, resulted in re-
stored TM healing even if plasminogen was administered
30 days after perforation. The distribution of inflamma-
tory cells in the perforated TM differed significantly be-
tween plasminogen-deficient and wild-type mice in
vivo. Plasminogen-deficient mice with initially normal
TMs showed spontaneous development of middle ear
effusion. Interestingly, in an otherwise healthy 10-year-
old boy with a history of chronic otitis media, low levels
of serum plasminogen were detected.32 Interaction of
PAI-1 with uPA prohibits catalytic activation of plasmin-
ogen to plasmin. High PAI-1 levels might, therefore,
result in similar clinical findings as seen in plasminogen
deficiency.
Furthermore, in skin wound healing, PAI-1, uPA, and
uPA receptor are expressed at the site of regenerative
epithelial outgrowths at the edge of the wound.33,34 Plas-
minogen-deficient mice showed impaired wound heal-
ing.35 In addition, Chen et al36 reported that uPA expres-
sion is increased on infection with Streptococcus
pneumoniae in an otitis media model in the rat. S pneu-
moniae is one of the major causative microbes of otitis
media in humans.37–39 We recognize that these findings
do not prove a role for PAI-1 in AOM, but we do feel that
they deserve further attention. Additional functional as-
says in an otitis model are needed to further investigate
the precise role of PAI-1 in AOM. These studies would
preferably also be directed toward analyzing the thera-
peutic role of PAI-1 inhibitors and plasminogen in over-
coming the effect of high PAI-1 expression and their
effects on recurrence of otitis media.
We found that PAI1 4G/4G had no effect on the initial
susceptibility to AOM as reflected by the lack of signifi-
cant differences between patients with AOM and control
subjects. This fits in our concept of tissue repair where
only once an episode of AOM has occurred may im-
paired tissue healing in 4G homozygous individuals fa-
cilitate microbial reinfection and the recurrence of otitis
media. We realize that the control group was not an
age-matched group without any AOM episodes, which
may have biased our results. However, occurrence of
AOM in the control subjects was 2 episodes per year
based on the prevalence of AOM in childhood. The
association between the PAI1 4G/4G genotype and the
otitis-prone condition remained significant even after
correction of the effect of the polymorphism on AOM
recurrence rates for gender, number of siblings, and both
age and age at first AOM for the children 4 years of
age. After 4 years of age we found a difference in the
distribution of the number of AOM episodes compared
with the younger children. AOM (and recurrence) has
its peak in the first years of life. Ongoing recurrence in
older children most likely selects a specific group that
differs from the larger group of 10% to 15% of all
children with recurrent AOM at early age. We possibly
selected for the older patients as a result of the nature of
the vaccination trial in which the patients included were
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more often otitis-prone children and particularly those
at older age who had ongoing recurrent disease.
We only studied 1 genetic polymorphism in a com-
plex multifactorial disease. As for many risk factors, only
a small increase in risk can be found, which may be
related to other risk factors as well. These may be both
genetic and environmental. The balance of the different
risk factors will determine the phenotype observed.
Studying multiple factors simultaneously does, however,
require large numbers of individuals. It must be men-
tioned that the association found in this study may re-
flect the result of linkage disequilibrium, meaning that
not the PAI1 polymorphism itself but a genetic variation
linked to this polymorphism is the actual disease-asso-
ciated genetic variant. Additional studies are, therefore,
required to confirm our findings. However, our data
show that studies of genes involved in the inflammatory
responses and tissue repair will be of significance in
understanding recurrent AOM.
CONCLUSIONS
Individuals homozygous for the 4G allele show an in-
creased risk for an otitis-prone condition, especially un-
der the age of 4 years. Impaired tissue integrity, because
of high PAI-1 levels in PAI1 4G homozygous individuals
once an episode of AOM has occurred, may possibly
facilitate bacterial colonization and, thereby, the recur-
rence of otitis media.
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